Cannabis-Based Products for Chronic Pain: An Updated Systematic Review
The DOI matches its Crossref record, with a small difference in title or year; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Benefits and harms of cannabinoids for chronic pain are uncertain. PURPOSE: To update an evidence synthesis on cannabinoids for chronic pain. DATA SOURCES: Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025. STUDY SELECTION: Randomized placebo-controlled trials. DATA EXTRACTION: Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method. DATA SYNTHESIS: = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms. LIMITATION: Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies. CONCLUSION: Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services (PROSPERO: CRD42021229579).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Self-citationPrevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016
Dahlhamer, J., Lucas, J., Zelaya, Nahin, R., Mackey, S., DeBar, L., Kerns, R., Von Korff, M., Porter, L., & Helmick, C. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6736a2 · Cited by 2,598
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
Cannabis-based medicines for chronic neuropathic pain in adults
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182.pub2 · Cited by 571
A LIKELIHOOD APPROACH TO META-ANALYSIS WITH RANDOM EFFECTS
Hardy, R., & Thompson, S. G. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960330)15:6<671::aid-sim205>3.0.co;2-5 · Cited by 527
Molecular Targets of the Phytocannabinoids: A Complex Picture
Morales, P., Hurst, D. P., & Reggio, P. H. (2017) · Progress in the Chemistry of Organic Natural Products · doi:10.1007/978-3-319-45541-9_4 · Cited by 454
Blake, D. R., Robson, P., Ho, M., Jubb, R. W., & McCabe, C. S. (2006) · Rheumatology · doi:10.1093/rheumatology/kei183 · Cited by 433
Cited by
Cooper, Z. D. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-04734
Hernandez‐Vallant, A., Kaskie, B. P., & Bobitt, J. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2662699
“…suggest that sub-stituting cannabis for opioids may reduce opioid use, medication side effects, and certain health risks 17–20 , more recent systematic reviews suggests that cannabis use may improve chronic pain in the short term while increasing side effects such as dizziness and sedation 21,22 .”
Odonkor, C. A., Karpe, D. A., Siddique, M. U., & Abd-Elsayed, A. A. (2026) · Pharmaceuticals · doi:10.3390/ph19081151 · Cited by 1
“…review and serial Annals of Internal Medicine syntheses, indicate that cannabis-based medicines—most consistently the THC: CBD oromucosal spray nabiximols—produce a small improvement in pain, on the order of 0.5–1.0 points on a 0–10 scale, corresponding to a small, standardized effect [53–55].”
InfluentialNeves, L. B. M., Daniel Domingues dos, S., Baldessarini, B. L., Laino, P. H., Neto, M. P. C., & Lima, B. C. (2026) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2026.08.007
Metadata
- Authors
- Chou, R., Fu, R., Ahmed, A. Y., & Morasco, B. J.
- Affiliations
- Oregon Health & Science University (US)
- Portland State University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2026-02
- Volume
- 179
- Issue
- 2
- Pages
- 230-241
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W7116922717
- Cited by
- 4
- References
- 53
- Citations by year
- 2026: 3
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- cannabinoids, chronic pain, neuropathic pain, tetrahydrocannabinol, cannabidiol, nabilone, dronabinol, adverse events, sedation, nausea, pain intensity
- MeSH terms
- Cannabidiol, Cannabinoids, Humans, Dronabinol, Randomized Controlled Trials as Topic, Chronic Pain, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabis-Based Products for Chronic Pain: An Updated Systematic Review. https://app.cochat.ai/papers/10.7326/annals-25-03152
- The paper
- Chou, R., Fu, R., Ahmed, A. Y., & Morasco, B. J. (2026). Cannabis-Based Products for Chronic Pain: An Updated Systematic Review. Annals of Internal Medicine. https://doi.org/10.7326/annals-25-03152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.